NLRP3
NLRP3 (NLR family pyrin domain-containing 3) is an intracellular innate-immune sensor and the defining component of the NLRP3 inflammasome, a multiprotein Signaling complex that detects diverse cellular stresses.
NLRP3 (NLR family pyrin domain-containing 3) is an intracellular innate-immune sensor and the defining component of the NLRP3 inflammasome, a multiprotein Signaling complex that detects diverse cellular stresses. It is expressed in many immune and barrier-associated cells, including Macrophages, monocytes, microglia, and intestinal epithelial or stromal cell populations. Rather than recognizing one unique microbial molecule, NLRP3 responds to convergent danger signals such as ion imbalance, mitochondrial dysfunction, oxidative stress, particulate substances, and tissue injury.
NLRP3 inflammasome activation generally involves an initial priming step, often mediated by NFKB1/NF-κB, followed by assembly of NLRP3 with the adaptor ASC and pro-caspase-1. Activated caspase-1 processes pro-interleukin-1 beta and pro-interleukin-18 into the mature proinflammatory cytokines Interleukin-1β (IL-1β) and Interleukin 18 (IL-18). Caspase-1 also cleaves gasdermin D (GSDMD), generating membrane pores that can cause inflammatory cell death known as pyroptosis. Excessive or persistent NLRP3 Signaling has therefore been investigated in inflammatory bowel disease, neuroinflammation, toxic tissue injury, sepsis, and other disorders involving inflammatory cytokines, oxidative stress, or altered host–Microbiota interactions.
NLRP3 is consequently an important pharmacological target. Current experimental strategies include small molecules that inhibit inflammasome assembly or NLRP3 activation, compounds that reduce NLRP3 expression, and interventions directed at upstream regulators such as NEK7, NF-κB, redox pathways, or the gut immune environment. The publication contexts provided here examine NLRP3 in relation to pyroptosis, anti-inflammatory natural products, synthetic inhibitors, nanoformulations, and systems-level therapeutic mechanisms.
Rebuilt from PubMed 18 Sept 2026 · no new papers today
Where the papers sit
22 papers study nlrp3 directly. The themes below are drawn from those 22. 1 paradigm shift follows.
-
NLRP3 Anti-Inflammatory Therapies : Small-molecule inhibitors, covalent domain probes and natural products are being developed to suppress NLRP3-driven inflammation. The work repeatedly connects inflammasome control with neuropathic pain, renal fibrosis, aging and immune-metabolic reprogramming. 7 papers · 31.8%
-
Pyroptosis and Cell Death : NLRP3-linked pyroptosis and related cell-death programs recur across colitis, cardiac aging, lung adenocarcinoma and melanoma. Oxidative stress, mitochondrial dysfunction, NEK7, Caspase-1 and purinergic signaling are common mechanistic targets. 5 papers · 22.7%
-
Neuroinflammation and Brain Injury : NLRP3, IL-1β and Caspase-1 inhibition is being pursued to limit inflammation after stroke, traumatic brain injury and seizures. Natural compounds and MCC950 recur as candidate interventions, with emerging attention to brain-heart inflammatory interactions. 5 papers · 22.7%
-
Inflammatory Signaling in Disease : NLRP3 and NF-κB signaling recur across diabetes-related neuroinflammation, preeclampsia, testicular toxicity and cancer immunotherapy. Oxidative stress, fatty-acid pathways and nanoparticle or natural-product interventions are explored, but no single clinical direction dominates. 5 papers · 22.7%
NLRP3 activity is context-dependent rather than uniformly pathological
The fatty acid-incorporated plasmid lipid nanoparticle cancer-immunotherapy study and the NLRP3-haploinsufficient aging-mice study challenge the assumption that NLRP3 activation is harmful and that reducing NLRP3 activity is uniformly therapeutic. FA-pLNP-induced NLRP3 inflammasome activity drove dendritic-cell hyperactivation, enhanced antigen presentation and migration, and improved the conditions for cytotoxic T-cell responses, whereas partial NLRP3 loss in aging mice produced compensatory NLRP1 overexpression and accelerated inflammatory aging 42003370Apr 42361162Jun. NLRP3 therefore emerges as a context- and dosage-dependent regulator whose activation can be therapeutically useful in cancer immunotherapy and whose partial inhibition can have adverse long-term consequences, changing the rationale from indiscriminate suppression to disease- and state-specific control.
Recent Findings on NLRP3
Inflammasome Inhibitor Discovery: QX-31 and D12 show that direct NLRP3 inhibition can target distinct regulatory regions, including the LRR and NACHT domains 42720495Sep42035603Apr. QX-31 covalently engages Cysteine 838, stabilizes an inactive NLRP3 conformation, and reversed renal fibrosis in organoids and murine injury models 42720495Sep. D12 blocked inflammasome assembly and prolonged survival in LPS-induced murine sepsis, while sorbicillinoid analogue 1i showed NLRP3-associated anti-inflammatory activity in macrophages 42035603Apr41921825Apr. Natural products and biological formulations also suppressed NLRP3 alongside antioxidant or barrier effects in neuropathic pain, aplastic anemia, and hair-follicle models 42308799Jun42497599Jul42669171Aug. However, Nlrp3 haploinsufficiency accelerated inflammatory aging through compensatory NLRP1 overexpression, supporting multiinflammasome inhibition rather than partial NLRP3 inhibition alone 42361162Jun.
Pyroptosis and Mitochondrial Stress: NLRP3-mediated pyroptosis links oxidative or mitochondrial stress with tissue injury in cardiac aging and colitis models 42264141Jun42061481Apr42007803Apr. TMAO activated oxidative stress, NLRP3, and Gasdermin D (GSDMD), whereas GSDMD deletion or TMAO-production inhibition reduced cardiac aging 42264141Jun. Nebivolol disrupted NEK7–NLRP3 interaction, and lactoferrin-modified liposomes increased colonic delivery while limiting systemic cardiac effects 42061481Apr. Oridonin nanomicrocapsules suppressed NLRP3, Caspase-1, and Interleukin-1β (IL-1β) while promoting epithelial regeneration and barrier repair 42007803Apr. Calcitriol reduced mitochondrial membrane potential, migration, IL-6, and NLRP3 in A375 melanoma cells, but not SK-MEL-28 cells, while ginsenosides engaged NLRP3 within a broader PANoptosis network in lung adenocarcinoma 42742798Sep41935997Apr.
Neuroinflammation After Brain Injury: MCC950 improved inflammatory markers, blood–brain barrier impairment, infarction, and neurobehavioral outcomes after stroke in aged mice 42631814Aug. Plant-derived compounds similarly reduced NLRP3-related neuroinflammation, seizures, microglial activation, neuronal damage, or behavioral abnormalities in rodent and cellular models 42679235Sep42090826May. Hydroxytyrosol studies prioritized the TXNIP–NLRP3–CASP1 module in traumatic brain injury through multi-omics, artificial intelligence, and transcriptomic analyses, but identified it for future experimental validation 42700807Sep. APOM deficiency worsened stroke-exacerbated myocardial infarction through Saa1, NF-κB, inflammasome-related signaling, and lipid disturbances, extending NLRP3 research toward brain–heart interactions 42622732Aug.
NF-κB and Oxidative Stress: Faecalibacterium prausnitzii and its short-chain fatty acids improved diabetes-associated affective behaviors alongside altered FFAR3/NF-κB/NLRP3 signaling 42617470Aug. Oxidative stress and NF-κB/NLRP3 activation also mediated chlorfenapyr-induced testicular toxicity, which nano-encapsulated rosmarinic acid reduced more effectively than crude rosmarinic acid 42478942Jul. Nanoformulated NUAK1 reduced reactive oxygen species, promoted autophagy, and suppressed NLRP3 in a preeclampsia mouse model 42151142May. AC3® produced cell-line-specific inflammatory effects, increasing NLRP3 in A375 cells but decreasing it in SK-MEL-28 cells while inhibiting proliferation and migration 42455469Jul. In contrast, palmitic-acid lipid nanoparticles deliberately promoted NF-κB priming and NLRP3 assembly in dendritic cells, using IL-1β release to enhance antitumor vaccination 42003370Apr.
Written from 22 PubMed abstracts, each one cited by PMID above. Published: 2026-08-20. Last written: 2026-09-17 by GPT. Drafted by language models from published abstracts; not medical advice.